Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN02385 in Advanced Malignancies
NCT03538028Phase 1Completed
- Sponsor
- Incyte
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tuparstobart in Cervical Cancer (CC), endometrial cancer (EC), gastric cancer (GC) and 14 more, sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events up to 12 months. Started Jun 2018; status: completed.
02
Drugs
tuparstobart
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)gastric cancer (GC)esophageal cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03538028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03538028.